At a critical time for cooperation on international challenges, not least the continuing COVID-19 pandemic and boosting vaccine rollout, leaders used the G7 as an opportunity to advance key issues for global health.
Foreign and Development G7 ministers committed to equitable access principles for COVID-19 vaccines in their post-meeting communiqué, including working with the pharmaceutical industry to encourage and support access on a voluntary basis and on mutually agreed terms.
Ministers also reaffirmed that investments in health systems will strengthen economic growth and our ability to respond to future pandemic threats, highlighting the importance of effective and well-functioning global value chains for the supply of vaccines, therapeutics and diagnostics.
The trade ministerial meeting ended with a communiqué with a specific section on Trade and Health which saw the G7 commit to work together on trade issues that can help boost global health and supply chain resilience.
The ABPI and IFPMA welcomed the positive signal the post-meeting statement sent that world leaders understand the unbreakable link between trade and resilient global supply chains.
Partners from all sectors were part of a global vaccine summit to discuss how we work together to building trust and confidence in vaccines globally. Julia Spencer, Co-Chair of the Vaccines Committee of IFPMA spoke on behalf of industry as part of a session on global collaboration.
The UK government announced ambitions for its G7 vaccine confidence activity designed to support global cooperation and more effective responses on vaccine confidence and addressing misinformation globally, including a new digital insight platform to provide global and local insight, as well as trends on vaccine confidence.
G7 Health Ministers met and agreed a communiqué highlighting a number of areas of agreement that are relevant to the pharmaceutical industry including a new G7 Therapeutics and Vaccines Clinical Trials Charter.
The UK also hosted a summit meeting between G7 Health Ministers and global life sciences CEOs to discuss the ambition of the 100 days mission set out by the Pandemic Preparedness Partnership (PPP) to which IFPMA President Jean-Christophe Tellier responded on behalf of industry.
The ABPI also responded to the announcement of the PPP saying that it’s vital that we build on our strength in R&D and manufacturing if we are to meet the health challenges of the future, achieve the 100 Day Mission set out today and make the UK a life science superpower.
G7 Finance Ministers met and, among other issues, discussed how to work together to tackle antimicrobial resistance and incentivise developing new antibiotics. The communiqué highlighted the severity of the AMR threat and commitment G7 countries to work together with industry to tackle the issue.
The ABPI and IFPMA responded to the issues discussed by Finance and Health ministers saying that it is positive that AMR is high on the global agenda, and that governments are committed to working with the pharmaceutical industry to find long-term solutions.
G7 leaders signed up to the Carbis Bay Declaration on health, vowing to take steps to ensure the global devastation caused by coronavirus is never repeated. The UK will also establish a new centre to develop vaccines to prevent zoonotic diseases from spreading between animals and humans.
The new Pandemic Preparedness Partnership (PPP) published its roadmap 100 Days Mission to respond to future pandemic threats, setting out how the G7 will work together to reduce the impact of future pandemics by making Diagnostics, Therapeutics and Vaccines available within 100 days.